


## PSYCHOTROPIC MEDICATIONS AND RAPID TRANQUILISATION

### RAPID TRANQUILISATION:

- The ideal sedative for rapid tranquilisation would be:
  - Easily administered
  - Rapid onset of action
  - Well tolerated with good side effect profile
  - No addictive properties
- Current options are antipsychotics and anxiolytics (most often benzodiazepines)
- IM route is preferred
- Beware preceding coingestion of alcohol or other respiratory suppressants
- Suggested algorithm shown below:

**Figure 285-1.**



- FDA black warning for droperidol and haloperidol in those with QTc prolongation, but not definitively linked to torsades
- All agents carry potential risks:
  - Excessive sedation
  - Aspiration
  - Adverse haemodynamics
  - Allergic reactions
- THE USE OF A SEDATIVE FOR CHEMICAL RESTRAINT CANNOT BE BASED ON STANDING ORDERS

### ANTIPSYCHOTICS (NEUROLEPTICS):

#### INDICATIONS:

- Used in the management of schizophrenia, acute mania, anxiety and agitation
- There are two main classes
  - TYPICAL:
    - Have low, medium or high potency that relates to the dosing of the drug for effective response
    - Low-potency drugs have more sedating qualities
    - High potency medications are more frequently associated with EPSE (tremors, rigidity, muscle spasms, akathisia)

| <b>Table 285-1 Commonly Prescribed Typical Antipsychotics</b> |                   |                         |  |
|---|-------------------|-------------------------|--|
| <b>Generic Name</b>   | <b>Brand Name</b> | <b>Relative Potency</b> | <b>U.S. Food and Drug Administration Warnings</b>    |
| <b>Phenothiazines</b>   |                   |                         |  |
| Chlorpromazine  | Thorazine         | Low                     |  |
| Mesoridazine  | Serentil          | Intermediate            | QT <sub>c</sub> prolongation                         |
| Thioridazine  | Mellaril          | Intermediate            | QT <sub>c</sub> prolongation                         |
| Perphenazine  | Trilafon          | Intermediate            |  |
| Trifluoperazine   | Stelazine         | High                    |  |
| Fluphenazine  | Prolixin          | High                    |  |
| <b>Thioxanthenes</b>  |                   |                         |  |
| Loxapine  | Loxitane          | Intermediate            |  |
| Thiothixene   | Navane            | High                    |  |
| <b>Dihydroindolone</b>  |                   |                         |  |
| Molindone   | Moban             | Intermediate            |  |
| <b>Butyrophenones</b>   |                   |                         |  |
| Haloperidol   | Haldol            | High                    | QT <sub>c</sub> prolongation and torsades de pointes |
| Droperidol  | Inapsine          | High                    | QT <sub>c</sub> prolongation and torsades de pointes |

- Medication induced QTc prolongation is not considered significant unless it is >500ms
    - However, QTc prolongation does not directly correlate with clinical risk of dysrhythmias or the development of torsades
  - ATYPICAL ANTIPSYCHOTICS:
    - Generally newer medications that more specifically target the dopamine receptors or inhibit the reuptake of serotonin
    - Adverse effects (sedation, EPSE, QTc prolongation and tardive dyskinesia) are generally reduced but not completely eliminated
    - Increased risk of CVA, cardiovascular events and mortality has been associated in older populations particularly particularly
    - Commonly prescribed agents shown below:

**Table 285-2 Commonly Prescribed Atypical Antipsychotics**

| Drug                       | U.S. Food and Drug Administration–Approved Indications   | Warnings and Common Side Effects (BLACK BOX WARNINGS IN CAPS)                                |
|----------------------------|--|--|
| Clozapine<br>(Clozaril)    | Treatment-resistant schizophrenia  | Sedation, dizziness, hypotension, tachycardia, salivation, weight gain, hyperthermia.        |
|                            | Reduction in the risk of recurrent suicidal behavior in schizophrenic or schizoaffective disorders | AGRANULOCYTOSIS, SEIZURES, MYOCARDITIS, OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS |
| Olanzapine<br>(Zyprexa)    | Schizophrenia  | CVAE, sedation, postural hypotension, hyperglycemia, weight gain, dizziness                  |
|                            | Bipolar disorder   |  |
|                            | Agitation associated with schizophrenia and bipolar I mania  |  |
| Quetiapine<br>(Seroquel)   | Bipolar mania  | NMS, hyperglycemia, sedation, hypotension, headache, weight gain                             |
|                            | Schizophrenia  | CATARACT FORMATION   |
|                            |  |  |
| Risperidone<br>(Risperdal) | Schizophrenia  | Extrapyramidal effects, hyperglycemia, hypotension, hyperprolactinemia, weight gain          |
|                            | Bipolar mania  |  |
| Ziprasidone<br>(Geodon)    | Schizophrenia  | Sedation, rash, dizziness, hypotension, hyperglycemia, extrapyramidal effects                |
|                            | Bipolar mania  |  |
|                            | Acute agitation in schizophrenic patients  | QT PROLONGATION AND RISK OF SUDDEN DEATH   |
| Aripiprazole<br>(Abilify)  | Schizophrenia  | NMS, CVAE, hyperglycemia, seizure, hypotension, headache, akathisia                          |
|                            | Bipolar disorder   |  |

- **SIDE EFFECTS OF ANTIPSYCHOTICS:**
  - Antipsychotics block dopamine receptors:
    - In the mesolimbic area accounts for their antipsychotic properties
    - Blockade in the nigrostriatal tract is responsible for the majority of motor side effects, including acute dystonias, akathisia and Parkinson syndrome
  - ACUTE DYSTONIA:
    - Most common side effect seen in ED
    - Muscle spasm of the neck, face and back most commonly
      - Can also get laryngospasm
      - Often misdiagnosed as a primary neurologic disorder or patient restlessness
    - TREAT WITH BENZTROPINE 1-2MG IV or DIPHENHYDRAMINE 25-50MG IV
    - Often recur despite dosage reduction or discontinuation of the offending agent → continue coadministration of benztropine or diphenhydramine
  - AKATHISIA:
    - Sensation of motor restlessness with a subjective desire to move
    - Often misdiagnosed as anxiety or exacerbation of psychiatric illness, akathisia is aggravated by subsequent increases in antipsychotic medications
    - Coexistent EPSE → cogwheel rigidity, shuffling gait
    - If possible, decrease the dose of antipsychotic, otherwise, trial of  $\beta$ -blocker (propranolol most often)
  - PARKINSONISM:

- Particularly common in elderly patients
- Usually begins in the first month of treatment
- Complete Parkinson syndrome can occur → bradykinesia, resting tremor, cogwheel rigidity, shuffling gait, masked facies, drooling
- Dose reduction plus anticholinergic medication is usually sufficient
- High potency antipsychotics have EPSE, whereas low-potency have more prominent anticholinergic and antiadrenergic effect
- ANTICHOLINERGIC EFFECTS:
  - Range from mild sedation to delirium
    - Peripheral manifestations → dry mouth/skin, blurred vision, urinary retention, constipation, paralytic ileus, cardiac dysrhythmia, angle-closure glaucoma
    - Central manifestations → dilated pupils, dysarthria and agitated delirium
- CARDIOVASCULAR EFFECTS:
  - Orthostatic hypotension, tachycardia
    - Likely related to anticholinergic and adrenergic blockade
    - Normally easily managed with IV fluids → vasopressors if severe
  - Effects on specific potassium channels in the myocardium which is believed to be responsible for QTc prolongation and induction of Torsades de Pointes
- NEUROLEPTIC MALIGNANT SYNDROME:
  - Uncommon IDIOSYNCRATIC REACTION to neuroleptic drugs
  - Manifested by:
    - Rigidity
    - Fever
    - Autonomic instability (tachycardia, diaphoresis, BP anomalies)
    - Confusional state
  - High mortality rate (20%)
  - All antipsychotics implicated (typical and atypical)
  - Management:
    - Cessation of antipsychotics
    - Hydration
    - Meticulous supportive care in ICU setting
    - Anticholinergics NOT HELPFUL
    - Dantrolene or bromocriptine often utilised

### Respiratory and circulatory support

Treatment of NMS must focus on supportive care, prevention of complications and cessation of dopamine antagonists (see [Antidotal therapy](#)). Aggressive fluid replacement is usually required and patients with hypotension should be given fluid replacement (see [Circulation](#)). In severe cases with muscle rigidity involving the chest wall, the patient may require respiratory support with intubation, sedation and paralysis.

### Cooling for hyperthermia

If the patient's temperature is greater than 39 °C, the patient should be cooled with tepid sponging and ice packs. Antipyretic drugs are ineffective (see [Key management issues](#)).

### Sedation

Many patients require sedation for confusion and agitation or, in severe cases, for intubation and paralysis. For drug and dosing recommendations, see [Sedation](#).

### Antidotal therapy

Although the effectiveness of antidotal therapy has not been demonstrated in controlled trials, clinical experience and case reports support the use of bromocriptine (a dopamine agonist). Use:

**bromocriptine 2.5 mg orally or via nasogastric tube, 8-hourly; the dose can be gradually increased based on clinical response up to 5 mg, 4-hourly.**



Bromocriptine should be titrated to clinical effect, looking for a lowering of the temperature and reduction of muscle rigidity. Severe NMS should be discussed with a clinical toxicologist or a unit experienced in treatment of this rare condition.

- OTHER SIDE EFFECTS:
  - Atypical antipsychotics have been associated with the additional side effects of seizures, weight gain and hyperglycaemia (independent of weight gain)
  - All atypical antipsychotics carry a black box warning citing their association with increased mortality in elder patients with dementia-related psychosis

## ANXIOLYTICS:

### INDICATIONS:

- Severe emotional distress, acute grief, or illicit substance use may warrant treatment with anxiolytics
- Sleep induction, sedation, treatment of seizures
- The main features distinguishing these agents are half-life and route of administration (see below)

### SIDE EFFECTS:

- **Relatively wide therapeutic window**
- COMMON SIDE EFFECTS → Somnolence, sedation, amnesia, ataxia
- Severe respiratory depression if coingested with alcohol or if given in overdose
- The abrupt cessation after long-term use is associated with a WITHDRAWAL SYNDROME → similar to alcohol withdrawal → restlessness, tremors, tachycardia, hypertension and seizures

**Table 285-3 Benzodiazepines Available in the U.S.**

| Generic Name     | Brand Name | U.S. Food and Drug Administration–Approved Indications | Route of Administration | Approximate Half-Life (hours) |
|------------------|------------|--|-------------------------|-------------------------------|
| Short Acting     |            |  |                         |                               |
| Estazolam        | ProSom     | Insomnia   | Oral                    | 10–24                         |
| Flurazepam       | Dalmane    | Insomnia   | Oral                    | 2.3                           |
| Midazolam        | Versed     | Sedation, anxiolysis, and amnesia:                     | Oral                    | 1.8–6.4                       |
|                  |            | Preoperative   | Parenteral              |                               |
|                  |            | Preprocedural  |                         |                               |
|                  |            | Preinduction   |                         |                               |
|                  |            | During mechanical ventilation                          |                         |                               |
| Temazepam        | Restoril   | Insomnia   | Oral                    | 3.5–18.0                      |
| Triazolam        | Halcion    | Insomnia   | Oral                    | 1.5–5.0                       |
| Long Acting      |            |  |                         |                               |
| Alprazolam       | Xanax      | Anxiety disorder                                       | Oral                    | 9–20                          |
|                  |            | Panic disorder   |                         |                               |
| Chlordiazepoxide | Librium    | Anxiety disorder                                       | Oral                    | 24–48                         |
|                  |            |  | Parenteral              |                               |
| Clonazepam       | Klonopin   | Panic disorder   | Oral                    | 30–40                         |
|                  |            | Seizure  |                         |                               |
| Clorazepate      | Tranxene   | Anxiety disorder                                       | Oral                    | 48                            |
|                  |            | Partial seizure  |                         |                               |
| Diazepam         | Valium     | Anxiety disorder                                       | Oral                    | 35                            |
|                  |            | Acute alcohol withdrawal                               | Parenteral              |                               |
|                  |            | Skeletal muscle spasm                                  | Rectal                  |                               |
|                  |            | Convulsive disorder                                    |                         |                               |
| Halazepam        | Paxipam    | Anxiety disorder                                       | Oral                    | 30                            |
| Lorazepam        | Ativan     | Status epilepticus                                     | Oral                    | 10–20                         |
|                  |            | Preal anesthesia                                       | Parenteral              |                               |
| Oxazepam         | Serax      | Anxiety disorder                                       | Oral                    | 4–15                          |
|                  |            | Acute alcohol withdrawal                               |                         |                               |
| Quazepam         | Doral      | Insomnia   | Oral                    | 25                            |

**ANTIDEPRESSANTS:**

- Prescribed for varying conditions ➔ depression, neurogenic pain or smoking cessation

**SSRI:**

- Because of their ease of dosing, safety profile and tolerability, SSRI are a first-line medication for depression
- COMMON SIDE EFFECTS:
  - Headaches, dizziness, sexual dysfunction, nausea, diarrhea, insomnia and agitation
  - Less commonly ➔ akathisia and apathy
  - These agents lack anticholinergic and cardiac effects typical of TCA
- WITHDRAWAL:
  - SSRI discontinuation syndrome has been described, more common with shorter half-life agents (sertraline, paroxetine) ➔ flu-like symptoms and delirium ➔ slow taper advised
- SEROTONIN SYNDROME:
  - POTENTIALLY LIFE-THREATENING

- Occurs when pharmacologic agents cause excessive serotonin neurotransmission (MAOI, tramadol, St John wort)
- Syndrome is manifest by:
  - Neuromuscular hyperactivity (tremor, myoclonus, clonus, hyperreflexia, seizure)
  - Altered mental status (restlessness, agitation, excitement, confusion)
  - Autonomic hyperactivity (tachycardia, tachypnoea, fever, diaphoresis)
  - GI irritability (nausea, vomiting, diarrhoea)
- TREATMENT IS SUPPORTIVE
- Prolonged washout of several days to weeks is required before other medications that increase serotonin levels can be started
- OVERDOSE:
  - Low lethality, even in overdose
  - In many cases, no symptoms develop

## TRICYCLIC ANTIDEPRESSANTS (AKA HETEROCYCLICS)

| Table 285-5 Commonly Used Heterocyclic Antidepressants |            |  |   |
|--|------------|--|---|
| Generic Name   | Brand Name | U.S. Food and Drug Administration–Approved Indications                                   | Comments  |
| Amitriptyline  | Elavil     | Depression   | Especially effective in endogenous depression   |
|  |            | Enuresis   | Off-label uses include treatment of insomnia, migraine, chronic pain, neurogenic pain, IBS  |
| Amoxapine  | Asendin    | Depression, panic disorders, bipolar disorder  | Especially effective in depression with agitation, neurotic or psychotic features<br>Can cause neuroleptic malignant syndrome   |
| Clomipramine   | Anafranil  | Depression, OCD, panic attack, narcolepsy, premature ejaculation, chronic pain, enuresis | Also used in pediatrics for OCD   |
|  |            |  | Under investigation for usefulness in preventing relapses in cocaine addicts and for anxiety disorders  |
| Desipramine  | Norpramin  | Depression   | Useful in chronic pain syndromes and attention-deficit disorders  |
| Doxepin  | Sinequan   | Depression   | Especially useful in depression associated with alcoholism or other organic disease and depression with psychotic features  |
|  |            |  | Off-label uses include anxiety disorder, extreme itching, insomnia, alcohol withdrawal, GI ulcerations (has histamine-2 receptor antagonism), chronic pain, headaches                     |
| Imipramine   | Tofranil   | Depression, childhood enuresis   | Prototypical heterocyclic antidepressant; currently second line after selective serotonin reuptake inhibitors   |
|  |            |  | Also used for panic attacks, ADHD, postconcussive syndrome, chronic pain  |
| Nortriptyline  | Pamelor    | Depression   | Off-label uses include treatment of panic disorder, IBS, chronic pain, neuralgia, and ADHD, and migraine prophylaxis; an effective smoking cessation aid and also useful for chronic pain |
| Maprotiline  | Ludiomil   | Depression   | Also used for the symptomatic treatment of anxiety or insomnia  |
|  |            |  | Strongly sedative in the first few weeks of treatment before antidepressant effects are present; especially useful in agitated depression   |

- Therapeutic effect related to secondary down-regulation of noradrenaline and serotonin postsynaptic receptors after initial blockade of presynaptic reuptake of noradrenaline and serotonin
- SIDE EFFECTS:

- Have LOW THERAPEUTIC INDEX, with therapeutic doses close to toxic doses
- Side effects are common and similar among the various drugs
- Toxicity increases with age and is higher with comorbid cardiac disease
- Majority of toxic effects → ANTICHOLINERGIC OR CARDIOTOXIC
- ANTICHOLINERGIC:
  - Particularly likely to occur with use of other anticholinergic drugs
  - Peripheral → dry mouth, metallic taste, blurred vision, constipation, paralytic ileus, urinary retention, angle-closure glaucoma
  - Central → sedation, mydriasis, agitation, delirium
- CARDIOVASCULAR EFFECTS:
  - Nonspecific T-wave changes
  - Prolonged QTc
  - Varying degrees of atrioventricular block
  - Atrial or ventricular arrhythmia
- OVERDOSE:
  - First presents with anticholinergic symptoms that develop within 120 minutes of ingestion
  - Condition then rapidly deteriorates in those with severe poisoning → coma, seizures and CV collapse may develop
  - The initial clinical presentation does not predict the seriousness of the overdose and mortality is high

### **MONOAMINE OXIDASE INHIBITORS:**

- Monoamine oxidase catalyses the oxidation of biogenic amines (tyramine, serotonin, dopamine and noradrenaline) throughout the body
- The therapeutic effect is probably related to their ability to increase noradrenaline and serotonin in the CNS
- Two agents → PHENELZINE, TRANYLCYPROMINE
- SIDE EFFECTS:
  - Orthostatic hypotension
  - CNS irritability:
    - Agitation
    - Motor restlessness
    - Insomnia
    - Autonomic side effects → dry mouth, constipation, urinary retention, delayed ejaculation
  - HYPERTENSIVE CRISIS:
    - Block oxidative deamination of tyramine and may precipitate a sometimes fatal hypertensive crisis when certain drugs or tyramine-containing foods are ingested
    - Drugs of concern → sympathomimetic amines, L-dopa, narcotics (especially pethidine), TCA
    - Tyramine-containing food → aged cheese, beer, wine, pickled herring, yeast, chopped liver, yoghurt, sour cream and fava beans



- ADMINISTRATION OF BETA-BLOCKERS IS CONTRAINDICATED as this may intensify vasoconstriction and worsen hypertension → nitroprusside and phentolamine are the preferred options

#### MISCELLANEOUS ANTIDEPRESSANTS:

**Table 285-6 Mechanisms of Action of Miscellaneous Antidepressants**

| Generic Name | Brand Name | Drug Class   |
|--------------|------------|--|
| Bupropion    | Wellbutrin | Dopamine reuptake inhibitor                                  |
| Mirtazapine  | Remeron    | Serotonin and norepinephrine reuptake inhibitor              |
| Trazodone    | Desyrel    | Serotonin (5-HT <sub>2</sub> ) antagonist/reuptake inhibitor |
| Venlafaxine  | Effexor    | Serotonin and norepinephrine reuptake inhibitor              |

#### **BUPROPION:**

- An effective and well-tolerated antidepressant that inhibits reuptake of dopamine and noradrenaline
- Less weight gain than TCA, and lower sexual side effect than SSRI
- Dose-related increase in seizures
  - Caution if taking anticonvulsants, has epilepsy or other condition that lowers the seizure threshold

#### **MIRTAZAPINE:**

- Antagonises inhibitory noradrenaline autoreceptors and thus causes increased release of noradrenaline
- Rapidly effective in treatment of anxiety and sleep disturbances related to depression

#### **VENLAFAXINE:**

- Approved for the treatment of adults with depression, generalised anxiety disorder
- It is structurally distinct from other antidepressants and conceptually is a combination of a TCA and SSRI in that it enhances both noradrenaline and serotonin (SNRI) through reuptake blockade
- No affinity for muscarinic, histaminic and  $\beta$ -adrenergic receptors
- Has caused serotonin syndrome
- False positive for PCP in drug screen

#### MOOD STABILISERS:

- Used in treatment of mood instability, most commonly bipolar disorder

| <b>Table 285-7 Mood Stabilizers</b> |                                |  |  |
|-------------------------------------|--------------------------------|--|--|
| <b>Generic Name</b>                 | <b>Brand Name</b>              | <b>FDA Approval Status for Use as Mood Stabilizer</b>  | <b>Comments/Side Effects (BLACK BOX WARNING IN CAPS)</b>             |
| Lithium carbonate                   | Eskalith, Lithonate, Lithotabs | Approved for treatment of BD                           | Effective for both phases of BD.                                     |
|                                     |                                |  | Narrow therapeutic window; toxicity common.                          |
| Valproic acid                       | Depakene, Depakote, Depacon    | Approved for treatment of BD                           | Dose-related side effects that clear with lower dosages.             |
|                                     |                                |  | Predominant side effects are GI.                                     |
|                                     |                                |  | Wide therapeutic window.   |
|                                     |                                |  | Monitor liver and renal functions.                                   |
| Carbamazepine                       | Tegretol                       | Only recently approved for BD, but used for many years | Dose-related side effects; AGRANULOCYTOSIS.                          |
|                                     |                                |  | Regular complete blood count and drug level monitoring required.     |
| Oxcarbazepine                       | Trileptal                      | Not FDA approved for BD but commonly used              | Does not cause blood dyscrasias.                                     |
| Lamotrigine                         | Lamictal                       | Approved; especially effective for bipolar depression  | Stevens-Johnson syndrome is rare complication but potentially fatal. |
| Topiramate                          | Topamax                        | Not FDA approved for BD but occasionally used          | Clinical trials show mixed results regarding usefulness in BD.       |

## LITHIUM:

- Used for both acute mania and maintenance in bipolar disorder
- Mechanism of action unknown, but may relate to reduction of dopaminergic function, enhancement of serotonergic function or reduction in excessive signalling by phosphatidylinositol system
- SIDE EFFECTS:
  - NARROW THERAPEUTIC WINDOW
  - GI distress, dry mouth, excessive thirst, fine tremors, polyuria, peripheral oedema are COMMON
  - Long-term problems → nephrogenic DI, benign diffuse goitre, hypothyroidism, skin rashes/ulceration, psoriasis
- TOXICITY AND OVERDOSE:
  - Severity is related to level and duration of elevated level but symptoms in acute overdose may not manifest for 48 hours
  - May result in neurologic sequelae and should be considered a medical emergency

**ANTICONVULSANTS AS MOOD STABILISER → SEE TABLE ABOVE**